Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Amylyx Pharmaceuticals Inc Common Stock (AMLX).
- Disclosed ownership: 4.9%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G/A Report for Amylyx Pharmaceuticals Inc Common Stock (AMLX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- AMLX
- Shares outstanding
- 106,756,073 shares
- Disclosed Ownership
- 5,273,750 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Oct 2025, 14:37:50 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 29 Jul 2025
- Next filing
- 30 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 4.9% ownership in Amylyx Pharmaceuticals Inc Common Stock (AMLX) on 30 Sep 2025."
What Changed
- Previous schedule filing date: 29 Jul 2025.
- Current filing was accepted on 30 Oct 2025, 14:37.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 4.9% | 5,273,750 | 0 | 538,257 | Ashley Grim | Head of Global Fund Administration |